Brokerages expect that Quanterix Corp (NASDAQ:QTRX) will announce $6.54 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Quanterix’s earnings. The highest sales estimate is $6.61 million and the lowest is $6.50 million. The firm is scheduled to report its next earnings report after the market closes on Wednesday, March 14th.
According to Zacks, analysts expect that Quanterix will report full year sales of $6.54 million for the current financial year, with estimates ranging from $22.76 million to $22.90 million. For the next fiscal year, analysts anticipate that the firm will post sales of $34.38 million per share, with estimates ranging from $33.82 million to $35.32 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Quanterix.
Several brokerages have recently commented on QTRX. Leerink Swann began coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 price objective for the company. BTIG Research began coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They set a “buy” rating and a $26.00 price objective for the company. Cowen began coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They set an “overweight” rating for the company.
Quanterix (NASDAQ:QTRX) opened at $19.85 on Tuesday. Quanterix has a one year low of $15.56 and a one year high of $24.81.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.